3D Bioprinting can not only produce normal tissue-like organs for regenerative medicine, but the vitro tumor models it build also exhibit significant preservation of histopathological features, biomarker expression, genetic alterations, and gene expression profiles that closely resemble their parentatumors. These tumor models not only serve as excellent models for drug development, but also demonstrate high accuracy in predicting patient responses to treatment, providing strong support for personalized precision treatment for cancer patients.

3D bioprinting technology reveals great potential in realizing individualized medical treatment, changing the existing treatment process, and helping pharmaceutical and medical companies develop more accurate drugs. Furthermore, it is expected to accomplish the closed-loop from individualized information collection and diagnosis to individualized medical product preparation and precise treatment scheme.